



Contralateral Prophylactic Mastectomy – An Opportunity for Shared Decision-Making

Shoshana M. Rosenberg, ScD, MPH and Ann H. Partridge, MD, MPH

Dana-Farber Cancer Institute, Boston MA

Most women who have contralateral prophylactic mastectomy (CPM) do not have clear clinical indications for undergoing the procedure, fueling concerns about overuse, as highlighted in the article by Hawley and colleagues.¹ Focusing on improving informed decision-making is one starting point. However, breast cancer surgical decisions are made at an emotional time when fully understanding and weighing the true risks (e.g., surgical complications, self-image, and sexual effects) and benefits (e.g. reduced risk of contralateral cancer) associated with CPM might be difficult for some patients. Anxiety and fear certainly hamper optimal decision-making,^{2,3} and greater psychological and emotional support may prove invaluable in this setting. Further complicating informed decision-making is the tendency for people to not believe that risk estimates apply to them personally.⁴

An underlying tension exists between “do no harm,” viewing CPM as medically unnecessary given the lack of demonstrated benefit on recurrence and survival, and respect for patient preferences and autonomy. While CPM might be considered over-treating women without clinical indications, it might still be the right choice for some women for risk reduction, cosmetic and/or emotional reasons. The Institute of Medicine⁵ recently categorized shared decision making in the context of cancer care as “suboptimal”, underscoring a need for better patient-clinician communication. Decision-making surrounding early breast cancer, with respect to CPM in particular, provides an opportunity to encourage a supportive, shared, decision-making approach. Not only should pros and cons of different treatment options be communicated, but there needs to be consideration of the patient's personal circumstances and perceptions, all the while addressing anxiety and concerns about breast cancer recurrence and new primary disease (and the distinction between the two). Finding balance around this issue, like the decision process itself, should be a goal shared by patients and clinicians alike.

Acknowledgments

Funding/Support: Dr. Rosenberg is the recipient of grant NIH 5 R25 CA057711 from the National Cancer Institute

References

1. Hawley ST, Jagsi R, Morrow M, et al. Is contralateral prophylactic mastectomy (CPM) overused? Results of a population-based survey. *JAMA Surgery*. 2013
2. Katz SJ, Morrow M. Contralateral prophylactic mastectomy for breast cancer: addressing peace of mind. *JAMA : the journal of the American Medical Association*. Aug 28; 2013 310(8):793–794.
3. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among Young Women With Breast Cancer: A Cross-sectional Survey. *Ann Intern Med*. Sep 17; 2013 159(6):373–381. [PubMed: 24042365]
4. Scherer LD, Ubel PA, McClure J, et al. Belief in numbers: When and why women disbelieve tailored breast cancer risk statistics. *Patient education and counseling*. Aug; 2013 92(2):253–259. [PubMed: 23623330]
5. IOM (Institute of Medicine). *Delivering high-quality cancer care: Charting a new course for a system in crisis*. The National Academies Press; Washington, DC: 2013.